Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications

Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications

Kynurenine (Kyn) pathway is a significant metabolic pathway of tryptophan (Trp). The metabolites of the Kyn pathway are closely correlated with numerous diseases. Two main enzymes, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO or TDO2), regulate the first and rate-limiting st...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Cancer 2019-01, Vol.10 (12), p.2771-2782
Hauptverfasser: Ye, Zixiang, Yue, Linxiu, Shi, Jiachen, Shao, Mingmei, Wu, Tao
Format: Artikel
Sprache:eng
Schlagworte:
Review
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2782
container_issue 12
container_start_page 2771
container_title Journal of Cancer
container_volume 10
creator Ye, Zixiang
Yue, Linxiu
Shi, Jiachen
Shao, Mingmei
Wu, Tao
description Kynurenine (Kyn) pathway is a significant metabolic pathway of tryptophan (Trp). The metabolites of the Kyn pathway are closely correlated with numerous diseases. Two main enzymes, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO or TDO2), regulate the first and rate-limiting step of the Kyn pathway. These enzymes are directly or indirectly involved in various diseases, including inflammatory diseases, cancer, diabetes, and mental disorders. Presently, an increasing number of potential mechanisms have been revealed. In the present review, we depict the structure of IDO and TDO and explicate their functions in various diseases to facilitate a better understanding of them and to indicate new therapeutic plans to target them. Moreover, we summarize the inhibitors of IDO/TDO that are currently under development and their efficacy in the treatment of cancer and other diseases.
doi_str_mv 10.7150/jca.31727
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6584917</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2250618052</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-84eef36c2989e1a833cb87ec849af72a727d0045b84d9d0048628d9df6b7da683</originalsourceid><addsrcrecordid>eNpVUctqwzAQFKWlCWkO_YHiY3twakm2JF8KJekjEAgE9yxked0oOLYr2YX-fZVHQ7qXHXaH2ccgdIujCcdJ9LjRakIxJ_wCDbGgPEwZiy_P8ACNndtEPmhKeEyv0YBikggukiHKVk0FQVMG89kyUHURZD6bOpiqWoN1-9IKKtVBEcyMA-XgUOzWEGRrsKqFvjM6mG_bymjVmaZ2N-iqVJWD8TGP0MfrSzZ9DxfLt_n0eRHqOMZdKGKAkjJNUpECVoJSnQsOWsSpKjlR_qYiiuIkF3GR7pBgRHhUspwXigk6Qk8H3bbPt1BoqDurKtlas1X2RzbKyP-d2qzlZ_MtWeJnYO4F7o8CtvnqwXVya5yGqlI1NL2ThCQRwyJKiKc-HKjaNs5ZKE9jcCR3RkhvhNwb4bl353udmH9vp7-15IL8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2250618052</pqid></control><display><type>article</type><title>Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ye, Zixiang ; Yue, Linxiu ; Shi, Jiachen ; Shao, Mingmei ; Wu, Tao</creator><creatorcontrib>Ye, Zixiang ; Yue, Linxiu ; Shi, Jiachen ; Shao, Mingmei ; Wu, Tao</creatorcontrib><description>Kynurenine (Kyn) pathway is a significant metabolic pathway of tryptophan (Trp). The metabolites of the Kyn pathway are closely correlated with numerous diseases. Two main enzymes, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO or TDO2), regulate the first and rate-limiting step of the Kyn pathway. These enzymes are directly or indirectly involved in various diseases, including inflammatory diseases, cancer, diabetes, and mental disorders. Presently, an increasing number of potential mechanisms have been revealed. In the present review, we depict the structure of IDO and TDO and explicate their functions in various diseases to facilitate a better understanding of them and to indicate new therapeutic plans to target them. Moreover, we summarize the inhibitors of IDO/TDO that are currently under development and their efficacy in the treatment of cancer and other diseases.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.31727</identifier><identifier>PMID: 31258785</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Review</subject><ispartof>Journal of Cancer, 2019-01, Vol.10 (12), p.2771-2782</ispartof><rights>Ivyspring International Publisher 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-84eef36c2989e1a833cb87ec849af72a727d0045b84d9d0048628d9df6b7da683</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584917/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584917/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27928,27929,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31258785$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ye, Zixiang</creatorcontrib><creatorcontrib>Yue, Linxiu</creatorcontrib><creatorcontrib>Shi, Jiachen</creatorcontrib><creatorcontrib>Shao, Mingmei</creatorcontrib><creatorcontrib>Wu, Tao</creatorcontrib><title>Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>Kynurenine (Kyn) pathway is a significant metabolic pathway of tryptophan (Trp). The metabolites of the Kyn pathway are closely correlated with numerous diseases. Two main enzymes, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO or TDO2), regulate the first and rate-limiting step of the Kyn pathway. These enzymes are directly or indirectly involved in various diseases, including inflammatory diseases, cancer, diabetes, and mental disorders. Presently, an increasing number of potential mechanisms have been revealed. In the present review, we depict the structure of IDO and TDO and explicate their functions in various diseases to facilitate a better understanding of them and to indicate new therapeutic plans to target them. Moreover, we summarize the inhibitors of IDO/TDO that are currently under development and their efficacy in the treatment of cancer and other diseases.</description><subject>Review</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVUctqwzAQFKWlCWkO_YHiY3twakm2JF8KJekjEAgE9yxked0oOLYr2YX-fZVHQ7qXHXaH2ccgdIujCcdJ9LjRakIxJ_wCDbGgPEwZiy_P8ACNndtEPmhKeEyv0YBikggukiHKVk0FQVMG89kyUHURZD6bOpiqWoN1-9IKKtVBEcyMA-XgUOzWEGRrsKqFvjM6mG_bymjVmaZ2N-iqVJWD8TGP0MfrSzZ9DxfLt_n0eRHqOMZdKGKAkjJNUpECVoJSnQsOWsSpKjlR_qYiiuIkF3GR7pBgRHhUspwXigk6Qk8H3bbPt1BoqDurKtlas1X2RzbKyP-d2qzlZ_MtWeJnYO4F7o8CtvnqwXVya5yGqlI1NL2ThCQRwyJKiKc-HKjaNs5ZKE9jcCR3RkhvhNwb4bl353udmH9vp7-15IL8</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Ye, Zixiang</creator><creator>Yue, Linxiu</creator><creator>Shi, Jiachen</creator><creator>Shao, Mingmei</creator><creator>Wu, Tao</creator><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190101</creationdate><title>Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications</title><author>Ye, Zixiang ; Yue, Linxiu ; Shi, Jiachen ; Shao, Mingmei ; Wu, Tao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-84eef36c2989e1a833cb87ec849af72a727d0045b84d9d0048628d9df6b7da683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ye, Zixiang</creatorcontrib><creatorcontrib>Yue, Linxiu</creatorcontrib><creatorcontrib>Shi, Jiachen</creatorcontrib><creatorcontrib>Shao, Mingmei</creatorcontrib><creatorcontrib>Wu, Tao</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ye, Zixiang</au><au>Yue, Linxiu</au><au>Shi, Jiachen</au><au>Shao, Mingmei</au><au>Wu, Tao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>10</volume><issue>12</issue><spage>2771</spage><epage>2782</epage><pages>2771-2782</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>Kynurenine (Kyn) pathway is a significant metabolic pathway of tryptophan (Trp). The metabolites of the Kyn pathway are closely correlated with numerous diseases. Two main enzymes, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO or TDO2), regulate the first and rate-limiting step of the Kyn pathway. These enzymes are directly or indirectly involved in various diseases, including inflammatory diseases, cancer, diabetes, and mental disorders. Presently, an increasing number of potential mechanisms have been revealed. In the present review, we depict the structure of IDO and TDO and explicate their functions in various diseases to facilitate a better understanding of them and to indicate new therapeutic plans to target them. Moreover, we summarize the inhibitors of IDO/TDO that are currently under development and their efficacy in the treatment of cancer and other diseases.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>31258785</pmid><doi>10.7150/jca.31727</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1837-9664
ispartof Journal of Cancer, 2019-01, Vol.10 (12), p.2771-2782
issn 1837-9664
1837-9664
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6584917
source PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Review
title Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T14%3A52%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20IDO%20and%20TDO%20in%20Cancers%20and%20Related%20Diseases%20and%20the%20Therapeutic%20Implications&rft.jtitle=Journal%20of%20Cancer&rft.au=Ye,%20Zixiang&rft.date=2019-01-01&rft.volume=10&rft.issue=12&rft.spage=2771&rft.epage=2782&rft.pages=2771-2782&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.31727&rft_dat=%3Cproquest_pubme%3E2250618052%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2250618052&rft_id=info:pmid/31258785&rfr_iscdi=true